Pancreatic Cancer Research

ResearcherMie UniversityNo recent work listed

Hiroyuki Sakurai

ORCID-verified (high confidence, 0.95), identity_conf@1As of 8 November 2026

Matched on ORCID iD 0000-0003-2757-6571; OpenAlex author ID A5102990759, A5112882713. Sources: OpenAlex.

Their work

Papers
15 (first author 0, last author 2)
Trials
0
Grants
0
Labs led
1
Collaborators
18
Papers, trials and grants by year

2012: 2 papers · 2013: none · 2014: 1 paper · 2015: 1 paper · 2016: none · 2017: none · 2018: 2 papers · 2019: 4 papers · 2020: none · 2021: 2 papers · 2022: 3 papers

Papers 15

  1. Concomitant splenic artery ligation has no preventive effect on left-sided portal hypertension following pancreaticoduodenectomy with the resection of the port… Last author DOI 10.1002/ags3.12545↗
  2. Role of Serum Carcinoma Embryonic Antigen (CEA) Level in Localized Pancreatic Adenocarcinoma: CEA Level Before Operation is a Significant Prognostic Indicator … Co-author DOI 10.1097/sla.0000000000004148↗
  3. Predictive risk factors for early recurrence in patients with localized pancreatic ductal adenocarcinoma who underwent curative-intent resection after preopera… Co-author DOI 10.1371/journal.pone.0264573↗
  4. Clinical significance and predictors of complete or near-complete histological response to preoperative chemoradiotherapy in patients with localized pancreatic… Co-author DOI 10.1016/j.pan.2021.08.011↗
  5. Phase I Study of Preoperative Chemoradiotherapy Using Gemcitabine Plus Nab-Paclitaxel for Patients Who Have Localized Pancreatic Ductal Adenocarcinoma With Con… Co-author DOI 10.1097/mpa.0000000000001902↗
  6. The clinical impact of portal venous patency ratio on prognosis of patients with pancreatic ductal adenocarcinoma undergoing pancreatectomy with combined resec… Co-author DOI 10.1016/j.pan.2019.01.020↗
  7. Comparative Study Between Gemcitabine-Based and Gemcitabine Plus S1-Based Preoperative Chemoradiotherapy for Localized Pancreatic Ductal Adenocarcinoma, With S… Co-author DOI 10.1097/mpa.0000000000001227↗
  8. Clinical Significance of Plasma Apolipoprotein-AII Isoforms as a Marker of Pancreatic Exocrine Disorder for Patients with Pancreatic Adenocarcinoma Undergoing … Co-author DOI 10.1155/2019/5738614↗
  9. Prognostic Nutritional Index After Chemoradiotherapy Was the Strongest Prognostic Predictor Among Biological and Conditional Factors in Localized Pancreatic Du… Co-author DOI 10.3390/cancers11040514↗
  10. Clinical Significance of Histological Effect and Intratumor Stromal Expression of Tenascin-C in Resected Specimens After Chemoradiotherapy for Initially Locall… Co-author DOI 10.1097/mpa.0000000000001022↗
  11. Survival Analysis in Patients with Pancreatic Ductal Adenocarcinoma Undergoing Chemoradiotherapy Followed by Surgery According to the International Consensus o… Last author DOI 10.3390/cancers10030065↗
  12. Spontaneous Rupture of an Intrasplenic Aneurysm After Pancreaticoduodenectomy for Pancreatic Ductal Adenocarcinoma. Co-author DOI 10.1016/j.jemermed.2014.11.025↗
  13. Gemcitabine-based chemoradiotherapy followed by surgery for borderline resectable and locally unresectable pancreatic ductal adenocarcinoma: significance of th… Co-author DOI 10.1097/mpa.0000000000000059↗
  14. Human equilibrative nucleoside transporter 1 expression is a strong independent prognostic factor in UICC T3-T4 pancreatic cancer patients treated with preoper… Co-author DOI 10.1007/s00534-011-0440-3↗
  15. Impact of histological response after neoadjuvant chemoradiotherapy on recurrence-free survival in UICC-T3 pancreatic adenocarcinoma but not in UICC-T4. Co-author DOI 10.1097/mpa.0b013e3182236442↗

Closest collaborators

The 18 strongest of 18 by collab_strength@1: shared papers, trials and grants, recent and small-team work weighing most.

  1. Shugo Mizuno · 15 shared papers, 2012–2022 · strength 1.26
  2. Yasuhiro Murata · 14 shared papers, 2012–2022 · strength 1.21
  3. Masashi Kishiwada · 14 shared papers, 2012–2022 · strength 1.21
  4. Naohisa Kuriyama · 12 shared papers, 2015–2022 · strength 1.16
  5. Aoi Hayasaki · 11 shared papers, 2018–2022 · strength 1.11
  6. Shuji Isaji · 13 shared papers, 2012–2022 · strength 0.96
  7. Kazuyuki Gyoten · 5 shared papers, 2021–2022 · strength 0.64
  8. Hiroyuki Kato · 7 shared papers, 2018–2022 · strength 0.59
  9. Yoshinori Azumi · 6 shared papers, 2018–2019 · strength 0.47
  10. Takahiro Ito · 3 shared papers, 2018–2022 · strength 0.36
  11. Toru Shinkai · 1 shared paper, 2021 · strength 0.11
  12. Taizo Shiraishi · 3 shared papers, 2012–2014 · strength 0.09
  13. Hiroyuki Inoue · 3 shared papers, 2012–2014 · strength 0.09
  14. Taijiro TAKEUCHI · 1 shared paper, 2019 · strength 0.08
  15. Warakorn Jaseanchiun · 1 shared paper, 2019 · strength 0.08
  16. Ken Ichikawa · 1 shared paper, 2019 · strength 0.08
  17. Hajime Sakuma · 1 shared paper, 2015 · strength 0.05
  18. Motoyuki Kobayashi · 1 shared paper, 2014 · strength 0.04

How to reach this person

A chain of introductions through people who have published, run trials or held grants together (warm_path@1: fewest links first, then the strongest). Built from public records only; no contact details are kept.